Infection Protection For The First 1000 days Of Life: Role of L. reuteri DSM 17938 On Microbial Communication Of Mother To Foetus
L. reuteri one of the most well researched probiotic species
To date 229 clinical trials with BioGaia's human strains of L. reuteri DSM 17938 have been performed in 18,536 individuals of all ages. The intake of L. reuteri DSM 17938 has been safe and not associated with any adverse events.
* L. reuteri DSM 17938 is derived from L. reuteri ATCC 55730. By removal of two plasmids carrying tet (W) tetracycline and lnu (A)lincosamide resistance genes, the new daughter strain is FREE from potentially transferable resistance genes.
Böttcher MF (2008) L. reuteri DSM 17938 increases anti-inflammatory cytokine in mother's colostrum
• The colostrum content of the cytokine TGF-beta 2 was significantly reduced while its content of the anti-inflammatory cytokine IL-10 increased.
• Supplementation with L. reuteri DSM 17938 during late pregnancy reduces breast milk levels of TGF‐β2, and low levels of this cytokine are associated with less sensitization and possibly less IgE‐associated eczema in breast‐fed infants.
Abrahamsson (2007) L. reuteri DSM 17938 reduced the frequency of IgE-associated eczema and sensitisation to food allergens in children
• Primary outcome was allergic disease, with or without positive skin prick test or circulating IgE to food allergens.
• Treated infants had less IgE-associated eczema at 2 years of age, especially those with allergic mothers. The lower incidence of allergic sensitisation in the L. reuteri DSM 17938 group implies that these children possibly run a reduced risk of respiratory allergy later in life.
• Link and guide to access to Live Webinar will be shared one(1) day prior to the Live Webinar.
• The sharing of Live Webinar log-in credentials to provide access to the Webinar by non-registered individual is prohibited.
Full Name as Per NRIC
Please include "-" eg: 012-3456789
Eg: O&G / Pediatrics/Neonatology
Place of Practice
Hospital / Medical Centre / Clinic Name
BioGaia L. reuteri DSM 17938, The only probiotic with scientific evidence in infantile colic.
Dr. Flavia Indrio (Department of Paediatrics University of Bari, Italy)
"Colic, constipation, and regurgitation can be prevented through early intervention with L. reuteri DSM 17938"
Dr. Flavia Indrio recommend microbial transfer from mom to newborns for at least 1000 days from conception to 2 years after birth for the life-long health of the child.
1. This webinar is for educational purposes and is intended for Healthcare Professionals only.
2. CPD points will be given out by National Specialist Register (NSR). Only registered specialists are eligible to obtain the CPD points.
3. Participants are not allowed to record or screenshot the presentation’s content during the meeting.
1. This webinar invitation is intended only for the individual or entity to whom it is registered and is confidential. If you are not the intended recipient, please notify us immediately by return e-mail or phone message, do not accept the invitation or join the meeting, and delete this message immediately. You are not to disseminate, distribute or copy any information contained herein.
By submitting this form, you provide your clear consent that BioGaia Malaysia (Pharma Ace Sdn Bhd) may collect, use, and/or processing of any of your personal information provided hereunder, or (if applicable) obtained by our organisation as a result of your registration, for the following purpose in accordance with the Personal Data Protection Act 2010 1) the processing of this registration 2) to contact you, through any communication channels.
I have read, understood and agree to the full terms & conditions of this form, including the statement above.
I would like to receive promotional information provided by BioGaia Malaysia, including offers, promotions and events in the future via email and text message.
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google.
Terms of Service